Rxivist logo

Protective Effects of STI-2020 Antibody Delivered Post-Infection by the Intranasal or Intravenous Route in a Syrian Golden Hamster COVID-19 Model

By Yanwen Fu, Junki Maruyama, Alok Singh, Reyna Lim, Arthur Ledesma, Daniel Lee, Laura Rivero-Nava, Jamie Ko, Ianne Rivera, Rachel A Sattler, John T. Manning, Lisa Kerwin, Heyue Zhou, Mark Brunswick, Damien Bresson, Henry Ji, Slobodan Paessler, Robert D. Allen

Posted 29 Oct 2020
bioRxiv DOI: 10.1101/2020.10.28.359836

We have previously reported that the SARS-CoV-2 neutralizing antibody, STI-2020, potently inhibits cytopathic effects of infection by genetically diverse clinical SARS-CoV-2 pandemic isolates in vitro, and has demonstrated efficacy in a hamster model of COVID-19 when administered by the intravenous route immediately following infection. We now have extended our in vivo studies of STI-2020 to include disease treatment efficacy, profiling of biodistribution of STI-2020 in mice when antibody is delivered intranasally (IN) or intravenously (IV), as well as pharmacokinetics in mice following IN antibody administration. Importantly, SARS-CoV-2-infected hamsters were treated with STI-2020 using these routes, and treatment effects on severity and duration of COVID-19-like disease in this model were evaluated. In SARS-CoV-2 infected hamsters, treatment with STI-2020 12 hours post-infection using the IN route led to a decrease in severity of clinical disease signs and a more robust recovery during 9 days of infection as compared to animals treated with an isotype control antibody. Treatment via the IV route using the same dose and timing regimen resulted in a decrease in the average number of consecutive days that infected animals experienced weight loss, shortening the duration of disease and allowing recovery to begin more rapidly in STI-2020 treated animals. Following IN administration in mice, STI-2020 was detected within 10 minutes in both lung tissue and lung lavage. The half-life of STI-2020 in lung tissue is approximately 25 hours. We are currently investigating the minimum effective dose of IN-delivered STI-2020 in the hamster model as well as establishing the relative benefit of delivering neutralizing antibodies by both IV and IN routes. ### Competing Interest Statement Sorrento authors own options and/or stock of the company. This work has been described in one or more provisional patent applications. HJ is an officer at Sorrento Therapeutics, Inc..

Download data

  • Downloaded 494 times
  • Download rankings, all-time:
    • Site-wide: 67,125
    • In microbiology: 4,369
  • Year to date:
    • Site-wide: 38,218
  • Since beginning of last month:
    • Site-wide: 41,636

Altmetric data

Downloads over time

Distribution of downloads per paper, site-wide